Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia.

被引：2
|
作者：
Hillmen, P
Skotnicki, AB
Robak, T
Mayer, J
Jaksic, B
Vukovic, V
Weitman, S
机构：
[1] Leeds Gen Infirm, PL-90131 Wakefield, England
[2] Jagiellonian Univ, Krakow, Poland
[3] Med Univ Lodz, Lodz, Poland
[4] Univ Hosp Brno, Brno, Czech Republic
[5] Univ Zagreb, Clin Hosp Merkur, Zagreb, Croatia
[6] Ilex Pharmaceut LP, San Antonio, TX USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2505.2505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2505
引用
收藏
页码：687A / 687A
页数：1
相关论文
共 50 条
  • [41] Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
    Autore, Francesco
    Innocenti, Idanna
    Corrente, Francesco
    Del Principe, Maria Ilaria
    Rosati, Serena
    Falcucci, Paolo
    Fresa, Alberto
    Conte, Esmeralda
    Limongiello, Maria Assunta
    Renzi, Daniela
    De Padua, Laura
    Andriani, Alessandro
    Pisani, Francesco
    Cimino, Giuseppe
    Tafuri, Agostino
    Montanaro, Marco
    Mauro, Francesca Romana
    Del Poeta, Giovanni
    Laurenti, Luca
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [42] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
    Montillo, Marco
    Tedeschi, Alessandra
    Ricci, Francesca
    Zaccaria, Alfonso
    Crugnola, Monica
    Spriano, Mauro
    Spedini, PierAngelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    De Blasio, Angelo
    Vismara, Eleonora
    Morra, Enrica
    Petrizzi, Valeria Belsito
    BLOOD, 2010, 116 (21) : 595 - 596
  • [43] FRONT-LINE THERAPY FOR ELDERLY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: BENDAMUSTINE PLUS RITUXIMAB OR CHLORAMBUCIL PLUS RITUXIMAB? REAL-LIFE RETROSPECTIVE MULTICENTER STUDY IN THE LAZIO REGION.
    Autore, F.
    Innocenti, I.
    Corrente, F.
    Del Principe, M. I.
    Rosati, S.
    Falcucci, P.
    Conte, E.
    Limongiello, M. A.
    Renzi, D.
    De Padua, L.
    Andriani, A.
    Pisani, F.
    Cimino, G.
    Tafuri, A.
    Montanaro, M.
    Mauro, F. R.
    Del Poeta, G.
    Laurenti, L.
    HAEMATOLOGICA, 2019, 104 : 103 - 104
  • [44] Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience
    Herishanu, Yair
    Goldschmidt, Neta
    Bairey, Osnat
    Ruchlemer, Rosa
    Fineman, Riva
    Rahimi-Levene, Naomi
    Shvidel, Lev
    Tadmor, Tamar
    Ariel, Aviv
    Braester, Andrea
    Shapiro, Mika
    Joffe, Erel
    Polliack, Aaron
    HAEMATOLOGICA, 2015, 100 (05) : 662 - 669
  • [45] Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL)
    Thieblemont, C
    Bouafia, F
    Hornez, E
    Dumontet, C
    Tartas, S
    Antal, D
    Lemieux, B
    Traullé, C
    Espinouse, D
    Salles, G
    Coiffier, B
    LEUKEMIA & LYMPHOMA, 2004, 45 (04) : 711 - 714
  • [46] Thalidomide (T) and fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): Results of a phase I trial.
    Chanan-Khan, AA
    Fallon, A
    Miller, K
    Bernstein, ZP
    Hernandez, F
    Alam, A
    McCarthy, P
    Mohr, A
    Czuczman, MS
    BLOOD, 2003, 102 (11) : 675A - 675A
  • [47] Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC plus G) Versus Chlorambucil Plus Obinutuzumab (Cbl plus G) As Front-Line Therapy
    Mulligan, Stephen P.
    Freeman, Jane A.
    Badoux, Xavier
    Eek, Richard
    Cull, Gavin
    Mackinlay, Naomi J.
    Murphy, Nicholas E.
    Carradice, Duncan P.
    Solterbeck, Ann C.
    Best, Oliver Giles
    Tam, Constantine S.
    Kuss, Bryone J.
    BLOOD, 2018, 132
  • [48] FRONT-LINE FLUDARABINE, CYCLOPHOSPHAMIDE, OFATUMUMAB CHEMOIMMUNOTHERAPY IN YOUNG (≤65 YRS) AND FIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. PRELIMINARY RESULTS OF THE PHASE 2, MULTICENTER GIMEMA STUDY LLC0911
    Mauro, F. R.
    Zaja, F.
    Molica, S.
    Coscia, M.
    Liberati, A. M.
    Piciocchi, A.
    Ilariucci, I.
    Russo, F.
    Tedeschi, A.
    Baraldi, A.
    Carella, A. M.
    Del Poeta, G.
    Cortelezzi, A.
    Gozzetti, A.
    Ferretti, A.
    Iannella, E.
    Del Giudice, I.
    Della Starza, I.
    De Propris, M. S.
    Marinelli, M.
    Nanni, M.
    Fazi, P.
    Vignetti, M.
    Neri, A.
    Specchia, G.
    Cuneo, A.
    Guarini, A.
    Foa, R.
    HAEMATOLOGICA, 2015, 100 : 28 - 28
  • [49] Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial
    Kater, Arnon P.
    Van Oers, Marinus H. J. H. J.
    Norden, Yvette
    Liu, Roberto D.
    Schipperus, Martin R.
    Chamuleau, Martine
    Nijland, Marcel
    Doorduijn, Jeanette K.
    van Gelder, Michel
    Hoogendoorn, Mels
    Croon-de Boer, Fransien
    Wittebol, Shulamit
    Kerst, Martijn
    Marijt, Willem
    Posthuma, Ward
    Raymakers, Reinier
    Schaafsma, Ron
    Dobber, Johan
    Kersting, Sabina
    Levin, Mark-David
    BLOOD, 2017, 130
  • [50] 2-chlorodeoxyadenosine (2-CdA) and prednisone (P) versus chlorambucil (Chl) and prednisone as a first line therapy in B-cell chronic lymphocytic leukemia (B-CLL).
    Robak, T
    BlasinskaMorawiec, M
    Blonski, JZ
    Krykowski, E
    Dmoszynska, A
    Skotnicki, AB
    Konopka, L
    Hellmann, A
    Kuratowska, Z
    Urasinski, I
    KotlarekHaus, S
    Maj, S
    BLOOD, 1997, 90 (10) : 2361 - 2361
12345